vs
Apellis Pharmaceuticals, Inc.（APLS）与HAIN CELESTIAL GROUP INC（HAIN）财务数据对比。点击上方公司名可切换其他公司
HAIN CELESTIAL GROUP INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$384.1M vs $199.9M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -30.2%，领先0.7%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -6.7%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -6.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
海恩 celestial集团是一家总部设在美国的国际食品与个人护理企业，主打天然食品与有机个人护理产品。公司1993年以海恩食品集团的名称成立，2000年与Celestial Seasonings合并后改用现名，在纳斯达克挂牌上市，旗下拥有艾拉厨房、Frank Cooper's、琳达麦卡特尼食品等多个品牌。
APLS vs HAIN — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $384.1M |
| 净利润 | $-59.0M | $-116.0M |
| 毛利率 | — | 19.4% |
| 营业利润率 | -25.6% | -25.7% |
| 净利率 | -29.5% | -30.2% |
| 营收同比 | -5.9% | -6.7% |
| 净利润同比 | -62.2% | -11.6% |
| 每股收益（稀释后） | $-0.40 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $384.1M | ||
| Q3 25 | $458.6M | $367.9M | ||
| Q2 25 | $178.5M | $363.3M | ||
| Q1 25 | $166.8M | $390.4M | ||
| Q4 24 | $212.5M | $411.5M | ||
| Q3 24 | $196.8M | $394.6M | ||
| Q2 24 | $199.7M | $418.8M | ||
| Q1 24 | $172.3M | $438.4M |
| Q4 25 | $-59.0M | $-116.0M | ||
| Q3 25 | $215.7M | $-20.6M | ||
| Q2 25 | $-42.2M | $-272.6M | ||
| Q1 25 | $-92.2M | $-134.6M | ||
| Q4 24 | $-36.4M | $-104.0M | ||
| Q3 24 | $-57.4M | $-19.7M | ||
| Q2 24 | $-37.7M | $-2.9M | ||
| Q1 24 | $-66.4M | $-48.2M |
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 18.5% | ||
| Q2 25 | — | 20.5% | ||
| Q1 25 | — | 21.7% | ||
| Q4 24 | — | 22.7% | ||
| Q3 24 | — | 20.7% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | -25.6% | -25.7% | ||
| Q3 25 | 48.7% | -1.9% | ||
| Q2 25 | -18.6% | -69.3% | ||
| Q1 25 | -50.0% | -31.0% | ||
| Q4 24 | -12.3% | -22.3% | ||
| Q3 24 | -24.0% | 0.8% | ||
| Q2 24 | -14.7% | 2.9% | ||
| Q1 24 | -36.0% | -6.4% |
| Q4 25 | -29.5% | -30.2% | ||
| Q3 25 | 47.0% | -5.6% | ||
| Q2 25 | -23.6% | -75.0% | ||
| Q1 25 | -55.3% | -34.5% | ||
| Q4 24 | -17.1% | -25.3% | ||
| Q3 24 | -29.2% | -5.0% | ||
| Q2 24 | -18.9% | -0.7% | ||
| Q1 24 | -38.5% | -11.0% |
| Q4 25 | $-0.40 | $-1.28 | ||
| Q3 25 | $1.67 | $-0.23 | ||
| Q2 25 | $-0.33 | $-3.03 | ||
| Q1 25 | $-0.74 | $-1.49 | ||
| Q4 24 | $-0.30 | $-1.15 | ||
| Q3 24 | $-0.46 | $-0.22 | ||
| Q2 24 | $-0.30 | $-0.03 | ||
| Q1 24 | $-0.54 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $68.0M |
| 总债务越低越好 | — | $388.0K |
| 股东权益账面价值 | $370.1M | $330.2M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $68.0M | ||
| Q3 25 | $479.2M | $47.9M | ||
| Q2 25 | $370.0M | $54.4M | ||
| Q1 25 | $358.4M | $44.4M | ||
| Q4 24 | $411.3M | $56.2M | ||
| Q3 24 | $396.9M | $56.9M | ||
| Q2 24 | $360.1M | $54.3M | ||
| Q1 24 | $325.9M | $49.5M |
| Q4 25 | — | $388.0K | ||
| Q3 25 | — | $708.6M | ||
| Q2 25 | — | $697.2M | ||
| Q1 25 | — | $701.4M | ||
| Q4 24 | — | $721.1M | ||
| Q3 24 | — | $732.8M | ||
| Q2 24 | — | $736.5M | ||
| Q1 24 | $93.1M | $769.9M |
| Q4 25 | $370.1M | $330.2M | ||
| Q3 25 | $401.2M | $445.0M | ||
| Q2 25 | $156.3M | $475.0M | ||
| Q1 25 | $164.2M | $696.7M | ||
| Q4 24 | $228.5M | $804.7M | ||
| Q3 24 | $237.1M | $963.7M | ||
| Q2 24 | $264.3M | $942.9M | ||
| Q1 24 | $266.7M | $944.5M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.8B | ||
| Q4 24 | $885.1M | $2.0B | ||
| Q3 24 | $901.9M | $2.1B | ||
| Q2 24 | $904.5M | $2.1B | ||
| Q1 24 | $831.9M | $2.1B |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 1.59× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | 0.35× | 0.82× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $37.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $37.0M | ||
| Q3 25 | $108.5M | $-8.5M | ||
| Q2 25 | $4.4M | $-2.6M | ||
| Q1 25 | $-53.4M | $4.6M | ||
| Q4 24 | $19.4M | $30.9M | ||
| Q3 24 | $34.1M | $-10.8M | ||
| Q2 24 | $-8.3M | $39.4M | ||
| Q1 24 | $-133.0M | $42.3M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HAIN
| Other | $175.5M | 46% |
| Snacks | $71.9M | 19% |
| Baby Kids | $53.6M | 14% |
| Western Europe | $50.5M | 13% |
| CA | $20.9M | 5% |
| Personal Care | $11.9M | 3% |
